- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), experts engage in a comprehensive dialogue about prostate cancer challenges and solutions in low and middle-income countries. The panel emphasizes the need for improved data collection and expanded radiotherapy access while exploring solutions through telemedicine and international collaborations, stressing that addressing global p...
|
- Details
- Andrea Miyahara speaks with Sheng-Yu Ku about a Journal of Clinical Investigation publication examining the role of Notch signaling in neuroendocrine prostate cancer. The research demonstrates that Notch signaling acts as a tumor suppressor in neuroendocrine prostate cancer by suppressing neuroendocrine differentiation and inducing prostate luminal lineage development. Dr. Ku's work reveals how No...
|
- Details
- Oliver Sartor speaks with Louise Emmett about combination therapy approaches with lutetium-PSMA in prostate cancer. The discussion explores various combination strategies, including promising results from the ENZA-p trial combining lutetium-PSMA with enzalutamide, which shows notable response rates in first-line mCRPC. They examine multiple potential combination approaches, including hormonal ther...
|
- Details
- Andrea Miyahira speaks with Ayesha Shafi about a study on AR coactivators CBP/p300 in prostate cancer. The research reveals that CBP/p300 expression increases as prostate cancer progresses to castration-resistant stages, correlating with poor patient survival. Through various preclinical studies, Dr. Shafi demonstrates that CBP/p300 plays a crucial role in DNA repair, particularly in homologous re...
|
- Details
- Raunak Shrestha discusses a published study on chromatin accessibility in advanced prostate cancer. The research, which represents the largest collection of ATAC-seq profiles in metastatic prostate cancer to date, reveals distinct chromatin accessibility patterns across different cancer subtypes. The study identifies 203 transcription factors associated with various metastatic prostate cancer subt...
|
- Details
- Phuoc Tran and Tim Showalter join Zachary Klaassen to discuss two presentations examining the ArteraAI prostate test in oligometastatic castration-sensitive prostate cancer. The conversation explores validation studies demonstrating the test's prognostic value for overall survival and its potential to predict benefit from metastasis-directed therapy using data from the STOMP and ORIOLE trials. The...
|
- Details
- Ursula Vogl discusses key prostate cancer highlights from ESMO 2024. The conversation explores three major trials across different disease stages: the PATCH trial evaluating transdermal estradiol versus LHRH analogs in non-metastatic disease, the ARANOTE trial examining darolutamide in metastatic hormone-sensitive prostate cancer, and the PEACE-3 trial investigating radium-223 plus enzalutamide in...
|
- Details
- Cathy Marshall discusses a non-randomized clinical trial evaluating olaparib without androgen deprivation therapy for high-risk biochemically recurrent prostate cancer following prostatectomy. The study shows promising results, particularly for patients with BRCA2 alterations, where all patients demonstrate PSA-50 responses. The conversation explores the trial design, patient outcomes, and safety...
|
- Details
- Wilbert Zwart joins Neeraj Agarwal to discuss research on epigenetic targeting in prostate cancer. The discussion examines histone markers in metastatic castration-resistant prostate cancer (mCRPC) patients to predict response to enzalutamide treatment. Using patient-derived xenografts and computational modeling, the research identifies HDAC3 as a key target and demonstrates synergistic effects wh...
|
- Details
- Evan Yu joins Zachary Klaassen to discuss the results of the ARROW trial. The study evaluates Iodine-131-LNTH-1095, a novel PSMA radioligand therapy, in combination with enzalutamide versus enzalutamide alone for metastatic castration-resistant prostate cancer patients who previously received abiraterone. While the trial meets its primary endpoint with significantly higher PSA decline rates in the...
|
